The extraordinary general meeting in XNK Therapeutics AB (“the Company”) was held on October 14, 2020, where the general meeting resolved in accordance with submitted proposals.
The following resolutions were passed at the general meeting:
To amend the Company’s articles of association, whereby, among other things, a record day provision was introduced in order to enable affiliation of the company’s shares with Euroclear Sweden.
To appoint PricewaterhouseCoopers AB, with the authorized public accountant Leonard Daun as principal auditor as the Company’s auditor for the period until the end of the next Annual General Meeting.
To authorize the Board of Directors to issue shares.
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
